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Experimental models in peritoneal dialysis: A European experi-
ence.
Background. The development of adequate animal models is
important for the in vivo study of selected aspects of peritoneal
dialysis (PD) that cannot be evaluated by an in vitro model, such
as peritoneal membrane transport, the influence of local defense
mechanisms, and for testing new osmotic agents and their bio-
compatibilities.
Methods. Our experience with animal models for PD, including
the acute Stockholm model in non-uremic rats, the acute and
chronic Amsterdam model in non-uremic rats, and the chronic
Gent model in uremic rats, is described.
Results. The Stockholm model proved to be useful in under-
standing the normal physiology of peritoneal transport, and for
testing new dialysis solutions and their biocompatibilities. It is a
rather simple and inexpensive model, and thus is suitable for
screening new solutions and additives. The Amsterdam model
permits the study of chemokines and mesothelial cell regeneration
in vivo, and is applied in a model of chronic peritonitis. The results
of the Gent model suggest that chronic peritoneal dialysis in
uremic rats is feasible for at least eight weeks. This model is,
however, very laborious, time consuming, and expensive.
Conclusion. Further improvement of the technique and in-
crease of the dialysis dose should result in a better and more
realistic model for peritoneal dialysis. It is hoped that in the future
these models will be useful to test the effects of long-term
intraperitoneal application of different dialysis solutions and
additives in uremic animals.
Experimental in vivo models have been used for many
years to study different aspects of peritoneal dialysis.
Although experimental lavage in dogs was performed as
early as the late 19th century [1], and the effects on
intraperitoneal volume of intraperitoneal solutions with
different osmolalities were already accurately described in
1894 [2], it was Putnam in 1923 who first characterized the
peritoneum as a dialyzing membrane (in the dog) [3]. His
work presented convincing evidence that the peritoneal
membrane was permeable in two directions, and therefore
he established the principles of solute transport and ultra-
filtration that are still true today.
In parallel with the development of the clinical CAPD
programs in the 1980s, the development of a growing
interest in the characteristics of peritoneal transport and
permeability stimulated the study of peritoneal physiology
in animals.
Studies on the peritoneal circulation [4], peritoneal-
plasma transport [5, 6], the kinetics of ultrafiltration,
lymphatic absorption [7–9], and the influence of infectious
peritonitis on the peritoneal morphology and transport
properties [10], have greatly increased our understanding
of the peritoneal membrane as a dialyzing organ. Perito-
neal pharmacokinetics and the pharmacologic alterations
of the peritoneal transport have also been carefully studied
in short-term dwells in unanesthetized rabbits [11].
After almost two decades of clinical experience, a num-
ber of major concerns remain among the peritoneal dialysis
community:
(1.) The viability of the peritoneal membrane during long-
term peritoneal dialysis and the ability of this membrane to
provide adequate fluid and solute removal in anuric patients
[12, 13]. It has now been recognized that conventional
CAPD treatment may not provide adequate dialysis in
patients without residual renal function [14]. Knowledge of
peritoneal fluid and solute transport is therefore funda-
mental in order to improve peritoneal dialysis efficiency. In
Europe, two Swedish groups have extensively used a rat
peritoneal transport model to study various transport char-
acteristics of peritoneal dialysis [15–20].
(2.) Despite the advances in peritoneal dialysis technology,
bacterial peritonitis remains the most frequent complication of
this form of therapy. In preventing peritonitis the local
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peritoneal defence mechanisms play a key role in the host’s
resistance to bacterial infection. Increasing our understand-
ing of these mechanisms is essential if we are to reduce the
negative consequences of peritoneal inflammation.
(3.) It is now well accepted that the dialysis solutions
currently used in clinical practice are not biocompatible [21].
The development of new and more biocompatible solutions
has been a focus of research in the peritoneal dialysis field
during the past two decades. An ideal solution should have
no systemic side effects, should not impair peritoneal host
defense, and should preserve long-term peritoneal mem-
brane integrity [22–26].
The majority of biocompatibility studies have used an in
vitro approach, and although this research has yielded
important functional information on the mechanisms of
dialysis fluid modulation of cell function, its relevance to
the in vivo situation is questionable. In particular, in vitro
systems do not provide information on long-term changes
to the peritoneal membrane (that occur over years in
humans) nor on peritoneal transport characteristics follow-
ing exposure to a new dialysis solution. Only with longitu-
dinal clinical studies and relevant in vivo models for
pre-clinical evaluation of new dialysis solutions will we be
able to address this issue [27]. Theoretically, animal models
could be used to study many aspects related to peritoneal
dialysis, including peritoneal membrane transport physiol-
ogy, new osmotic agents’ solution biocompatibility, the
effects of pharmacological manipulation and studies of
peritoneal local defense mechanisms against infection.
At present research in this field has been hindered by the
lack of suitable animal models for chronic peritoneal
dialysis. Most studies using animal models have performed
experiments that have lasted only a few hours and have
injected the fluids directly into the abdominal cavity rather
than delivered them via an implanted catheter. Only rarely
has peritoneal dialysis been applied to uremic animals.
Only by comparing chronic peritoneal dialysis in uremic
animals with non-uremic animals can the effects of uremia
per se on structural and functional changes of the peritoneal
membrane be better delineated from the effects of dialysis
itself.
EXPERIMENTAL ANIMAL MODELS USED IN
PERITONEAL DIALYSIS
The majority of investigators have used rat or rabbit
models of PD. Both animals have their advantages and
disadvantages. Rats are easy to maintain, economical, and
models of stable chronic renal failure in the rat have been
extensively described. On the negative side, rats are small
and have a relatively large peritoneal surface area, making
infused dialysate difficult to recover, which results in small
quantities of the effluent being available for analysis.
Moreover, important mesothelial changes may occur after
intraperitoneal implantation of biomaterials like silicone or
Dacron into the peritoneal cavity [28].
Recently, an experimental model of chronic peritoneal
dialysis in normal rats has been described [29]. Peritoneal
dialysis was performed in 10 non-uremic rats, dialyzed
twice daily for four weeks with a 3.86% glucose-containing
fluid. Several effects on the peritoneal membrane were
described including: (a) healing of the peritoneum after
catheter implantation; (b) decreased cell count in the
drained dialysate; (c) decreased permeability of the perito-
neum to glucose and total protein; (e) increased volume of
drained dialysate; (f) damage to the peritoneal membrane
due to its exposure to peritoneal dialysis solution with
concomitant increases in hyaluronic acid levels in dialysate;
and (g) tendency of the peritoneum to thicken when
compared to non-dialyzed animals. To our knowledge,
there is only one study describing the effects of “long-term”
peritoneal dialysis in uremic rats [35]. Uremia was induced
by controlled resection of renal tissue. Animals were dia-
lyzed three weeks with one exchange per day. Stable blood
values of creatinine and urea were observed.
Several groups of investigators have used domestic rab-
bits as a model system. These animals can tolerate a
peritoneal catheter for quite long periods of time, and they
are rarely subject to peritonitis. Experimental models of
peritoneal dialysis in uremic rabbits had already been
established in the early 1980s [30], and more recently the
effect of the intraperitoneal infusion of dextrose and amino
acids on the appetite of both normal and uremic rabbits
have been studied [31, 32]. Uremia was induced by subtotal
nephrectomy, resulting in blood urea levels between 0.86
and 1.99 g/liter and serum creatinine levels of 2.47 and 8.78
mg%. Only single dwell studies were performed in these
uremic animals.
Recently, a non-uremic rabbit model with a PD catheter
in situ has been used to characterize the peritoneal trans-
port parameters by standard peritoneal permeability anal-
ysis [33]. A daily dwell of one hour with a 3.86% glucose
solution was used over a four week period. After correction
of the solute transport parameters to body surface area,
similar values to humans were obtained. In a more recent
study [34], the same model was used to investigate the
influence of amphotericin B and HgCl2 on peritoneal
transport in rabbits.
In the present article, we summarize the efforts of three
European research groups to establish rat models for the
study of several different aspects of peritoneal dialysis
physiology and pathology. The first part describes the
experience of the Stockholm group with a model of peri-
toneal dialysis in non-uremic rats. Short-term peritoneal
exchanges were applied to the study of the physiology of
small solute and water transport, the effects of non-glucose
osmotic agents, the biocompatibility of dialysis solutions,
and the effects of addition of pharmacological substances.
The second part summarises studies performed in an acute
and chronic rat model by the Amsterdam group on the
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pathophysiology of peritonitis and of host defense mecha-
nisms in peritoneal dialysis. The third part describes the
studies of the Gent group in developing a model for chronic
peritoneal dialysis over a prolonged period (8 weeks) in
uremic rats. Detailed studies were performed on food and
fluid intake of the animals, the daily diuresis, and perito-
neal and residual renal fluid and solute removal.
THE ACUTE RAT MODEL TO STUDY PERITONEAL
TRANSPORT
The model currently used in Stockholm is a recent
modification of a rat peritoneal transport model that was
established in the early 1990s [19, 20, 36]. In general, a four
hour dwell with frequent dialysate and blood sampling is
performed in anesthetized male Sprague-Dawley rats. In-
traperitoneal dialysate volume is estimated from the dilu-
tion of intraperitoneal 131I-human serum albumin (RISA),
with corrections made for the elimination of RISA from the
peritoneal cavity and the sample volumes [37]. The perito-
neal fluid absorption rate is estimated as the coefficient of
RISA elimination from the peritoneal cavity, KE (ml/min),
and the transcapillary ultrafiltration rate is calculated as net
volume change plus KE. The direct lymphatic absorption of
fluid from the peritoneal cavity is assessed as the clearance
of RISA from the dialysate to the blood, KEB (ml/min).
KEB is calculated from the rate of increase of RISA
concentration in plasma divided by the average intraperi-
toneal RISA concentration [38]. The plasma volume is set
at 3.6 ml/100 g body wt [38, 39]. The peritoneal solute
transport characteristics are evaluated using the dialysate
over plasma aqueous concentration ratios (D/P), of the
solutes under investigation [40], clearances and the diffu-
sive mass transport coefficients (KBD, ml/min) [41, 42].
The model describes the net change of the solute con-
centration in peritoneal dialysate over time, which is equal
to the rate of solute flow between blood and dialysate due
to combined diffusion, convective transport, and peritoneal
absorption of the solute. The D/D0 for glucose [calculated
as the dialysate glucose concentration (D) divided by the
glucose concentration in the fresh dialysis solution (D0)]
and KBD for glucose are used to evaluate the peritoneal
transport of glucose.
In recent years, this transport model has been used to
study: (a) different osmotic agents and buffers, such as
glucose, polyglucose, oligopeptides, albumin and bicarbon-
ate; (b) different additives, such as hyaluronan, docusate
sodium, atrial natriuretic peptide (ANP), nitroprusside,
and amphotericin B; (c) different dialysis regimens, such as
high dialysate fill volume with 1.36% and 3.86% glucose
solutions; and (d) biocompatibility of the currently used
peritoneal dialysis solutions.
In this article, the effects of different osmotic agents and
of selected additives on peritoneal transport kinetics and
the potential use of the model for the study of biocompat-
ibility aspects will be discussed.
Different osmotic agents: Polyglucose solution,
oligopeptides solution
Polyglucose solutions can remove a significant quantity
of fluid during long duration dwells despite the low osmo-
lality of the solution (280 mOsm/kg; Fig. 1). During short
time dwells, however, there is net fluid absorption. Perito-
neal fluid removal is strongly related to the magnitude of
increase in dialysate osmolality in the peritoneal cavity.
Only when the dialysate osmolality increases to levels
higher than that of plasma does the intraperitoneal volume
starts to increase. In a parallel ex vivo study, there was a
marked increase in the osmolality of polyglucose dialysate
after 24 hours of storage of the samples in vitro, which
suggested that this increase was partially due to enzyme
Fig. 1. Intraperitoneal volume (A) and dialysate osmolality (B) mea-
sured immediately after the samples were taken versus dwell time with
7.5% polyglucose solution versus dwell time (N 5 11) (mean 6 SD). The
intraperitoneal volume was initially decreased and then started to increase
after one hour of the dwell, which was strongly associated with an
osmolality gradient between dialysate and plasma. Dashed line represents
the plasma osmolality during the dwell.
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degradation of the glucose polymer [43]. These results
imply that the current combination of concentration and
molecular weight of glucose polymer in the polyglucose
solution may not be ideal for peritoneal dialysis, especially
for shorter dwell times.
It is well known that for high molecular weight solutes
the increased osmotic efficiency per molecule is out-
weighed by the disadvantages associated with the increases
in molecular mass required to produce a high osmotic
efficiency. In fact, it has been suggested that there is an
optimal molecular weight of an osmotic agent (for short
and medium term dwell), balancing the benefits of increas-
ing molecular size (and the increased osmotic efficiency
associated with this size increment), and the disadvantage
of the increases in solute mass per molecule, that is, the
increasing concentration in g/liter. According to theoretical
calculations this seems to occur at a molecular weight of
around 1000 daltons, which is much lower than the average
molecular weight of the current formulation of glucose
polymer (16800 daltons) [44]. In support of this theoretical
calculation, a preliminary study in our rat model has found
that a 4% oligopeptide solution (average molecular weight
700 daltons) produces a higher net ultrafiltration than a
2.27% glucose solution and only marginally lower than a
3.86% glucose solution (Fig. 2).
It is perhaps not surprising that several recent studies
suggest that polyglucose solutions may result in better
ultrafiltration (UF) during peritonitis and in patients with
high peritoneal transport rates [45, 46]. The transport rate
of amylase (an enzyme capable of degrading glucose poly-
mer) may be considerably higher in patients with high
peritoneal transport rates, and the dialysate amylase levels
in the dialysate during peritonitis are significantly higher
than control effluents [47, 48]. In the present rat model
peritonitis does result in increased degradation of glucose
polymer, increased dialysate osmolality and better UF [49].
Addition of nitroprusside to polyglucose solutions resulted
in an increased peritoneal degradation of glucose polymer
[50]. Although there may be some species difference in the
peritoneal fluid and solute transport [43], these studies
support the previous clinical observations. Further studies
are needed, however, to confirm if polyglucose degradation
plays a significant role in its ability to alter ultrafiltration in
vivo.
The study of different additives to the dialysate
Improving the efficiency of the peritoneum as a dialyzing
organ is one of the major goals in improving the therapy.
Several pharmacological substances have been tested ex-
perimentally and clinically [11]. None of them, however,
have been accepted into clinical practice. It is known that
peritoneal fluid absorption substantially decreases the effi-
ciency of peritoneal dialysis. In CAPD patients peritoneal
fluid absorption reduced potential net ultrafiltration by
83.2 6 10.2%, urea clearance by 16.9 6 1.9% and creati-
nine clearance by 16.5 6 1.9% in one six hour exchange
[51]. The contribution of peritoneal fluid absorption to low
dialysis efficiency is more significant in high transporters
when a 1.36% glucose solution is used [52, 53]. Therefore,
reducing the peritoneal fluid absorption should be a effec-
tive way to improve PD adequacy (with regards to the
Fig. 2. Intraperitoneal volume versus dwell time for 3.86% glucose
dialysate (M, N 5 8), 2.27% glucose dialysate (E, N 5 8) and 4%
oligopeptides solution (, N 5 8). The intraperitoneal volume at the end
of the dwell was significantly higher in the 3.86% glucose dialysate and 4%
oligopeptide solution groups as compared to the 2.27% glucose dialysate
group (both P , 0.01), whereas no significant difference was found
between the former two groups.
Fig. 3. Changes in fluid volume versus dwell time for 1.36% glucose
solution (M, E and ; N 5 6) and 1.36% glucose solution with 0.01%
hyaluronan solution (f, F and ; N 5 6). Open and solid squares
represent the net ultrafiltation volume; open and solid circles are the
peritoneal total fluid absorption; Open and solid triangles are the trans-
capillary ultrafiltration volume. The net ultrafiltration was significantly
higher in the hyaluronan group as compared to the control group (P ,
0.05, ANOVA, repeated measurements), which was due to a significantly
lower peritoneal fluid absorption. Data are from Wang et al [83]; used
with permission.
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removal of both small solutes and fluid), especially when
high dialysate fill volumes are used.
Using the rat model, we have observed that peritoneal
absorption can be significantly reduced and peritoneal
small solute clearance increased by adding 0.01% hyaluro-
nan, a long polysaccharide chain made up of repeating
disaccharide units of N-acetylglucosamine and glucuronic
acid to peritoneal dialysis solutions (Fig. 3) [54]. The effect
of hyaluronan is potentially due to the accumulation of a
restrictive filter “cake” of hyaluronan chains at the tissue-
cavity interface [54]. Hyaluronan plays an important role in
tissue hydraulic conductivity and has been shown to exhibit
a high resistance to water flow. It can thus act in tissue as a
barrier against rapid changes in tissue water content [55].
These promising results now need to be confirmed in
clinical studies.
Atrial natriuretic peptide (ANP), a hormone with well
known diuretic and vasodilating properties, has recently
been reported to increase peritoneal fluid formation and
increase peritoneal solute clearance. The addition of ANP
to peritoneal dialysis solutions significantly increases peri-
toneal fluid removal in the rat by decreasing the peritoneal
fluid absorption rate (by 51%). It also decreases the direct
lymphatic absorption by 43% [56]. Its mechanism of action
is still, however, not clear.
The effects of dioctyl sodium sulphosuccinate (DSS),
amphotericin B, and nitroprusside have also been investi-
gated in this rat model. DSS is a surfactant and has been
shown to increase peritoneal small solute clearance. DSS,
similar to another surfactant, phosphatidylcholine was
found to increase peritoneal fluid and small solute removal
whereas the peritoneal solute transport rate did not change
[57]. Intraperitoneal use of amphotericin B has been re-
ported to increase ultrafiltration during short peritoneal
dwell in rabbits [58]. However, in the rat model, ampho-
tericin B did not increase peritoneal fluid removal after
four hours of dwell. Higher D/P and KBD values as well as
higher clearances for potassium were observed, suggesting
a possible local release of potassium due to a cytoxic effect
of amphotericin B. It was therefore concluded that ampho-
tericin B would not be useful for the improvement of
peritoneal dialysis efficiency [59].
Biocompatibility of peritoneal dialysis solutions
The bioincompatibility of dialysis solutions has been
suggested as one of the reasons for the changes in the
structure and function of the peritoneum during long-term
peritoneal dialysis [60]. There is still, however, little direct
evidence that more biocompatible dialysis solutions would
preserve the function of the peritoneum.
Recently, the biocompatibility of the dialysis solution has
been explored using a rat model [19]. Ten days exposure to
3.86% glucose dialysis fluid reduced the peritoneal fluid
removal, which was partially due to the fluid absorption
rate being increased, whereas the small solute transport
rate was increased (Table 1). Net fluid removal and small
solute transport rate (except glucose) did not change
significantly following exposure to 1.36% glucose solution.
The peritoneal lymphatic absorption rate and glucose
absorption rate, however, were significantly increased in
both solutions, suggesting a possible physiological adapta-
tion to the infused glucose containing dialysate. It should
be noted that the diffusive mass transfer coefficient for
glucose (KBD glucose) was equal to or even higher than the
mass transfer coefficient for urea, which is in contrast with
results obtained in patients, as such this may be a species-
specific phenomenon [36, 37].
This study suggests that daily exposure to currently used
glucose-based peritoneal dialysis solutions may result in
functional changes to the peritoneum. The decreased fluid
removal in the 3.86% glucose solution group, due to
increased fluid reabsorption, results in decreased clear-
ances for small solutes as well as increased glucose absorp-
tion, and represents changes that in the human may prevent
the peritoneum from long-term use for peritoneal dialysis.
These results indicate that functional studies of peritoneal
transport characteristics after daily infusion of dialysis fluid
may be a useful model to assess the in vivo effects of
peritoneal dialysis solutions.
In summary, this acute peritoneal transport model in the
Table 1. Peritoneal fluid and small solute transport parameters after ten days exposure to 1.36% glucose dialysis solution (LGS group) or to 3.86%




KE KEB KBDglucose KBDurea
ml/min
Control 8 3.8 6 2.1 0.054 6 0.010 0.008 6 0.001 0.32 6 0.006 0.28 6 0.12
LGS 8 1.3 6 4.9 0.058 6 0.024 0.020 6 0.004a 0.43 6 0.08a 0.31 6 0.10
HGS 8 0.0 6 1.9a 0.072 6 0.008b 0.021 6 0.004a 0.47 6 0.06a 0.51 6 0.14b
Data are mean 6 SD. Abbreviations are: net UF, net ultrafiltration volume at 4 hour of the dwell; KE, total RISA elimination rate representing the
fluid absorption rate from the peritoneal cavity; KEB, RISA elimination rate to the blood from the peritoneal cavity representing the peritoneal
lymphatic absorption; KBDglucose, diffusive mass transfer coefficient for glucose estimated by using modified Babb-Randerson-Farrell model and setting
the sieving coefficient equal to 0.55; KBdurea, diffusive mass transfer coefficient for urea estimated in the same way as for glucose.
a P , 0.05 compared with the control group
b P , 0.05 compared with the other two groups
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normal rat could help us understand the physiology of
peritoneal transport. It can be used to study various aspects
of peritoneal dialysis, including new dialysis solutions with
different osmotic agents and additives, and may prove
useful in testing the in vivo effect of the dialysis solutions.
A RAT MODEL FOR THE STUDY OF PERITONEAL
DEFENSE MECHANISMS
The macrophage is the predominant cell type in the
peritoneal cavity of healthy animals as well as in patients
undergoing peritoneal dialysis, and is thought to play a key
role in the local host defense against infection. Phagocyto-
sis and killing of microorganisms by peritoneal cells seem to
be essential in an early stage of contamination. Studies of
macrophages in CAPD patients suggested that a chronic
sterile inflammation exists in the peritoneal cavity. Charac-
terization of the immuno-phenotypes and immuno-effec-
tors of the peritoneal cavity have confirmed these observa-
tions [61–63]. Analysis of the peritoneal cellular immune
system shortly before a clinical peritonitis showed a de-
creased phagocytic capacity by peritoneal macrophages
[64].
The continuous exposure of the peritoneal cavity to
commercial dialysis fluid itself might reduce the local
antibacterial defence mechanisms. A rat model was there-
fore developed to investigate the influence of PD fluids on
the function of peritoneal cells and the structure of the
peritoneal membrane. Previous studies revealed that a
single intraperitoneal (i.p.) administration of peritoneal
dialysis fluid induced an acute exudate, compared to that
observed after saline infusion [65]. A rapid influx of
neutrophilic granulocytes and exudate macrophages oc-
curred into the peritoneal cavity. These findings strongly
suggested that frequent i.p. injections of PD fluid might
lead to a chronic inflammation, comparable with the situ-
ation present in CAPD patients.
An experimental infection model in the rat was estab-
lished in which the effect of inoculum and volume on
bacterial killing was investigated [66]. A suspension of 0.5
ml, containing 3 3 108 Staphylococcus aureus (ATCC
25923) was injected into the peritoneal cavity of the rat.
These organisms were cleared in a time-dependent fashion
over a three to five day period.
In the PD setting, short dwell times reduced the perito-
neal defence mechanisms, including bacterial killing [67].
The effect of prior injection of PD fluid on bacterial
clearing was then studied in an animal infection model. The
data clearly showed that prior injection of PD fluid com-
promised peritoneal antibacterial defence. It was found
that the glucose in PD fluid was responsible for the
impairment of antibacterial defence [68, 69].
A major drawback of this infection model was that only
the effect of a single administration of PD fluid was
explored. The main aim of later studies was to develop a
peritoneal dialysis model in the rat. Initially, an experimen-
tal model was established lasting 33 hours, with exchanges
of fluids every three hours during the day and an overnight
dwell of 15 hours. After the first three hour exchange,
bacteria were administered in the infected animal group. In
this approach, a silicone tube of 615 cm length was placed
and secured in the peritoneal cavity and subcutaneously
tunneled to the neck region. The end of the canula was
exposed through an incision in the skin and plugged. As
described in other comparable models, prophylactic antibi-
otics were administered via a feeding tube. After the
animals had recovered, the exchange of fluids (Dianeal,
glucose 1.36 to 3.86% solutions, or physiological saline,
respectively) was performed by administration of 10 ml of
Fig. 4. Total volume of peritoneal fluid
collected at various intervals after the start of
dialysis, with physiological saline (), fluid
with 1.36% glucose (E), fluid with 2.27%
glucose (l) or fluid with 3.86% glucose (f).
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PD fluid via the cannula and collection of the effluent three
hours later, followed by the administration of fresh PD
fluid. In summary, in the PD group effluents varying from
6 to 9 ml were collected at all of the different time-points
(except for physiological saline), whereas the overnight
dwell resulted in volumes of 1 ml or less (Fig. 4). In the
infection group, the volumes of the collected fluids were
lower, especially between 24 to 33 hours. Moreover, in the
PD group, the number of cells collected ranged from 1 to
3 3 107, and consisted for about 40% of neutrophilic
granulocytes. In contrast, higher cell numbers (3 to 8 3
107), with a higher percentage of neutrophilic granulocytes
were found in the infection group.
This model has allowed the evaluation of immunological
events occurring during short-term peritoneal dialysis.
However, several problems appeared, such as the necessity
for continuous antibiotic therapy, and the recovery of high
percentages of neutrophilic granulocytes in the control
Fig. 5. Ultrathin section of omentum tissue six hours after injection of Staphylococcus aureus. Abbreviations and symbols are: MC, mesothelial cell;
MØ, macrophage; arrows, S. aureus; arrowheads, digested S. aureus.
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group, indicating ongoing inflammation in the infection
group. In addition, compartimentalization of the peritoneal
cavity due to fibrin and adhesion formation occurred that
complicated fluid collection. These problems made the
model unsuitable for studying long-term effects of exposure
to PD fluids.
One of the possible solutions to the “mechanical” cath-
eter obstruction could be the performance of an omentec-
tomy. However, the omentum (and especially the milky
spots) is an important source of both mesothelial cells and
macrophages [70, 71]. Omentectomy impairs antibacterial
defence [70, and unpublished observations]. Despite the
fact that others have been successful in establishing a
continuous rat PD model after omentectomy [29], we have
avoided this procedure, since this may have implications for
the immune status of the animal.
Chemokines produced by mesothelial cells and macro-
phages play a central role in the regulation of inflammatory
cell influxes in CAPD patients, as they are important for
bacterial killing [72–77]. We have recently established in a
rat model that after an i.p injection, Staphylococcus aureus
bacteria were clearly visible within mesothelial cells in vivo
(Fig. 5) [78]. These data suggest a potentially important
role of the mesothelium in bacterial clearance and cell
activation in vivo, and confirm in vitro findings [74].
Whether different PD fluids influence the mesothelial
handling of bacteria and thereby regulate the inflammatory
response in vivo upon bacterial challenge has yet to be
investigated.
To study the role of mesothelial cells in vivo during PD
and to start possible intervention studies on chemokines
and mesothelial cell regeneration, an appropriate animal
model was required. We therefore developed a rat model
to determine the effects of PD fluid on the morphology of
the peritoneum and on local host defence mechanisms [79].
In this model a peritoneal catheter was implanted in the
peritoneal cavity. This catheter (;15 cm in length), con-
nected to a mini-vascular access port, was inserted into the
peritoneal cavity and the port was tunneled subcutaneously
to the neck of the rat. After the implantation of the
catheter, rats were given 2 ml of saline with 1 U/ml heparin
daily to allow healing of the incision in the abdomen. Six
days later, PD fluid instillation was commenced. The six
days period was implemented because direct installation of
10 ml PD fluid immediately after surgery often resulted in
subcutaneous leakage of the PD solution, resulting in
inflammation. The animals continued to gain weight during
the experiments. About 20% of the animals were excluded
from the experiments because outgrowth by the omentum
obstructed the catheter. Using this approach, daily instilla-
tion of PD fluid in the rat peritoneal cavity can be
performed for at least 20 weeks without significant compli-
cations. This technique makes it possible to compare the
cellular composition of these animals at several time inter-
vals and to analyze whether this cellular composition is
related to the intraperitoneal chemokine secretion profile.
In addition, changes in the mesothelial monolayer at
several time points as well as other morphological changes
in the peritoneum can be studied. The results in this model
show that four weeks after fluid instillation an initial
increase in total cells is followed by a decline with a lower
cell count after 12 weeks. The cellular composition 12
weeks after daily PD-fluid installation closely resembles
that found in PD patients (Table 2). The number of
neutrophilic granulocytes ranges from 1 to 7%, indicating
that no infection or acute inflammation are present. The
percentages of lymphocytes at 12 weeks range between 10
to 25% with about 70% macrophages, resembling a chronic
sterile inflammation as described above. Morphological
changes of the mesothelial cell monolayer are detected in
this model. A higher density of cells is observed after four
weeks, and foci of young mesothelial cells within activated
mesothelium are found after 12 weeks. Twelve weeks after
daily PD-fluid installation appears to be a good time to
observe mesothelial damage and regeneration.
This latter model clearly does not completely mimic the
PD situation, as no exchanges are carried out and the
animal is not uremic. Advantages of this model are due to
the use of a mini vascular access port, which removes the
necessity for the administration of antibiotics and provides
access for the performance of an omentomectomy. In
addition, the cellular composition resembles the human
situation (low percentages of neutrophilic granulocytes)
and the experimental treatment is very well tolerated by the
animals. Finally, this model can be combined with the
previous infection model to study whether long-time expo-
sure to PD fluid further impairs peritoneal host defence
and to determine what effects different PD fluids have on
these different parameters. Also, the role of the mesothe-
lial cell in vivo in this infection model can now be fully
investigated.
A MODEL OF CHRONIC PERITONEAL DIALYSIS IN
UREMIC RATS
Chronic renal failure was surgically induced by partial
nephrectomy in male adult Wistar rats. Under general
anesthesia with pentobarbital 50 mg/kg, the left kidney was
exposed through a flank incision, and both the anterior and
posterior poles and approximately one third of the remain-
ing cortical tissue from the exterior lateral part of the
kidney were removed. This resulted in a total resection of
.85% of the renal tissue. Bleeding was controlled by the
Table 2. Comparison of cellular composition of effluents of CAPD
patients and PD rats
Macrophages Lymphocytes Neutrophils
CAPD patientsa 70–75% 15–20% 2–5%
PD rats 12 weeks 65–75% 10–25% 1–7%
a Betjes et al, Kidney Int 43:641–648, 1993
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application of thrombin (2500 U/ml) to the cut surfaces.
One week later, the right kidney was removed after ligaton
of the blood vessels and ureter under general anesthesia.
Three weeks later, a silicone catheter (CH15; International
Medical) was introduced into the abdominal cavity, strictly
following the protocol as described by Miller, Findon and
Rowe [35]. The catheter was pushed over a trocar that was
then used to create a subcutaneous track ending at the back
of the neck of the animal. Omentectomy was not per-
formed. After carefully securing the catheter and closure of
the surgical wounds, the silicone catheter was closed by a
Luer-Lock adaptor.
Chronic peritoneal dialysis was started at least three
weeks after the insertion of the catheter. Each morning, the
Luer-Lock adaptor was removed, a polyethylene, gas-
sterilized catheter (PE 240; Beckton- Dickinson, USA) was
passed down the permanent indwelling catheter and rinsed
with 15 ml of pre-warmed saline. After draining this fluid,
15 ml pre-warmed dialysis fluid, either containing 1.36% or
2.27% glucose (Bieffe Company, Italy) was instilled by
gravity for a dwell time of three hours in the unanesthetized
animal. Ceftazidim 125 mg/liter, gentamicin 8 mg/liter, and
ciprofloxacine 25 mg/liter were added to every dialysate
exchange.
After the first dwell of three hours, the effluent was
drained as completely as possible and a second dwell with
15 ml of dialysis fluid was begun for another three hours. At
the end of the second dwell, the fluid was drained, and the
peritoneal cavity was rinsed with 15 ml of saline. After
draining this rinse, the Luer-Lock adaptor was closed and
the animal returned to its cage. On Monday and Friday of
each week, blood was sampled by puncture of the tail vein.
Creatinine, urea, electrolytes, osmolality, total protein, and
glucose were measured in each effluent and in the 24-hour
urine volumes, collected on Monday and Friday of each
week. The blood samples were assayed for creatinine, urea,
osmolality, total protein, and hematocrit. Each animal was
housed in a metabolic cage and daily food and fluid intake,
24-hour urine volumes and quantities of feces were mea-
sured. Body weight was followed for the entire duration of
the experiment. Urea and creatinine were enzymatically
measured [80, 81]. Electrolytes were assayed by ion-selec-
tive electrodes, glucose by the hexokinase method [82],
total protein by the Biuret method and osmolality by
standard osmometry.
In 13 animals, chronic renal failure was induced by the
same surgical method and a peritoneal catheter was im-
planted in 4 of them. These animals were housed in
metabolic cages but peritoneal dialysis was not performed,
and they served as time controls for the dialyzed animals.
The clinical and biological parameters that are presented
in the dialyzed group are from the 12 animals that were
dialyzed for at least four weeks. These data are compared
with the results obtained in the 13 non-dialyzed uremic
animals. The evolution of body weight, daily food and water
intake, and daily urinary volume in both dialyzed and
non-dialyzed uremic animals are given in Table 3.
The mean body weight in the PD group before the start
of PD was 320 6 45.5 g and remained stable. In the non-PD
animals, a tendency for a decreasing body weight was
observed. Although peritoneal dialysis had apparently no
impact on either food or fluid intake, the daily food intake
of non-uremic animals of the same body weight (N 5 25)
and housed under the same circumstances, fluctuated
around 30 6 4.2 g. Over the same period (8 weeks), the
non-uremic animal’s body weight increased by 150 g.
In non-uremic rats of the same body weight, (N 5 25),
the daily fluid intake was 40 6 6.7 ml. It should be noted
that the fluid intake of the uremic rats was much higher
than in non-uremic animals, but not different between the
dialyzed and non-dialyzed animals. It is remarkable to note
that in contrast to the non-dialyzed animals, the daily urine
output dramatically increased after the start of peritoneal
dialysis. The evolution of the serum creatinine, hematocrit
values, residual urine and peritoneal creatinine clearances,
drain volumes, D/P creatinine values, the percent glucose
absorption per dwell of three hours, and the leukocyte
counts in effluent are presented in Table 4.
The starting serum creatinine values were significantly
higher compared to non-uremic animals; in our laboratory,
the blood urea and serum creatinine levels, the latter
determined with the enzymatic assay, in non-uremic rats
(N 5 25), were 0.22 6 0.035 mg% and 26 6 4 mg%,
respectively. In contrast with non-dialyzed animals, both
blood urea and serum creatinine values significantly de-
creased during the first two to three weeks of peritoneal
Table 3. Evolution of body weight, daily food and water intake and daily urinary volume in dialyzed and non-dialyzed uremic animals
Weeks Before 1 2 3 4 5 6 7 8
Body weight g PD 320 6 45.5 320 6 32.7 316 6 39.0 313 6 32.9 326 6 34.1 313 6 39.7 306 6 34.1 311 6 37.2 318 6 14.1
non-PD 316 6 43.0 305 6 31.2 302 6 39.6 282 6 40.5 295 6 55.0 307 6 49.5 301 316 6 36.8 235
Daily food PD 18.3 6 5.1 20.2 6 4.5 20.0 6 2.8 19.0 6 4.8 16.7 6 2.9 14.3 6 7.5 17.2 6 3.6 16.3 6 2.6 17.8 6 3.3
intake g non-PD 18.6 6 3.5 19.1 6 3.5 17.5 6 4.7 18.7 6 3.33 20.1 6 3.3 18.0 6 1.9 21.7 20.2 16
Daily fluid PD 63.9 6 22.8 71.1 6 15.1 67.5 6 14.2 65.2 6 20.6 57.8 6 13.9 48.5 6 25.3 62.8 6 10.4 60.5 6 18.0 59.6 6 12.1
volume ml non-PD 60.5 6 8.7 57.2 6 9.1 55.1 6 8.9 52.7 6 6.92 59.0 6 6.0 58.5 6 8.0 67.7 50.3 50
Daily urine PD 38.3 6 9.3 49.0 6 15.8 52.1 6 14.6 51.2 6 19.0 55.5 6 19.2 39.5 6 16.3 56.5 6 15.3 58.1 6 20.6 50.5 6 6.2
volume ml non-PD 36.9 6 7.4 36.3 6 4 37.7 6 8 34.1 6 7.3 37.5 6 11.6 36.6 6 11.5 33.4 34.9 36.5
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dialysis. Thereafter, values comparable with those obtained
at start of PD were obtained. The renal creatinine clear-
ance was lowered to 0.29 6 0.1 ml/min in both groups of
rats at the start of dialysis, which is approximately 12% of
the normal creatinine clearance in non-uremic animals of
the same strain and body weight in our laboratory (2.47 6
0.72 ml/min). There was a tendency of the residual creati-
nine clearance to decrease with time on dialysis.
The peritoneal data were calculated on 2 3 3-hour
exchanges on two days per week. The instilled volume
being 15 ml, it is clear that the drained volume was always
lower. This explains the relatively low calculated peritoneal
creatinine clearances, which represent only approximately
20% of the renal clearances. The D/P creatinine values
remained high, with a calculated transperioneal glucose
absorption ranging around 90 to 93% over three hours.
This should be compared with a percent glucose absorption
of 85 to 91% after four hours in single dwell studies with a
2.27% glucose solution in non-uremic animals in our
laboratory. From the first week on, a dramatic increase in
total leukocyte count in the drained dialysate was observed.
Differentiation of these leukocytes by FAC scan analysis
revealed the majority to be lymphocytes and macrophages.
Based on the relative increase of the granulocytes in the
dialysate, 16 episodes of peritonitis were observed in a total
number of 307 dialysis weeks. Cultures of the dialysate
yielded coagulase-negative staphylococci on 7 occasions,
Streptococcus agalactiae on 3 occasions, and Escherichia coli
in 2 and Corynebacterium spp. on 1 occasion.
There was no difference in the cumulative survival rate
of the PD animals after the start of dialysis compared with
the survival of the non-dialyzed uremic animals over the
total of eight weeks. Twenty-nine uremic animals were
successfully prepared and started peritoneal dialysis.
Twelve animals were dialyzed for at least four weeks, eight
for six weeks, and five for eight weeks. When the calcula-
tion of the eight-week survival rate was limited to the
dialyzed or non-dialyzed animals surviving at least four
weeks, a statistically greater survival of the dialyzed animals
was observed (Fig. 6).
These preliminary results on “chronic” peritoneal dialy-
sis in uremic animals deserve comment. At first glance it is
disappointing that the cumulative survival of the uremic
animals was only minimally increased by peritoneal dialysis,
compared to the non-dialyzed uremic animals. This lack in
overall improved survival is explained by the relatively high
mortality of the dialyzed animals occurring in the first three
to four weeks after the initiation of peritoneal dialysis. In
the animals surviving these first weeks, however, the mor-
tality during the next four weeks was substantially lower
than in the uremic, non-dialyzed animals. These results are
therefore encouraging and justify in our opinion to con-
tinue these studies. It is clear that this model should be
improved further to better imitate the clinical peritoneal
dialysis setting.
Two major problems remain still unsolved. The first is
Fig. 6. Cumulative survival dialyzed (dotted line) versus non-dialyzed
(solid line) uremic animals surviving at least four weeks.
Table 4. Evolution of the biological data, residual urine and peritoneal function in uremic animals
Weeks Before 1 2 3 4 5 6 7 8
Blood creatinine PD 1.72 6 0.5 1.33 6 0.4 1.36 6 0.4 1.47 6 0.4 1.84 6 0.4 1.70 6 0.2 1.72 6 0.2 1.79 6 0.4 1.69 6 0.4
mg% non-PD 2.07 6 0.82 1.97 6 0.65 2.18 6 0.8 2.1 6 0.6 1.95 6 0.95 2.22 6 1.2 1.90 2.11 2.2
Hematocrit % PD 34.0 6 3.6 31.0 6 3.9 32.0 6 3.3 32.0 6 5.7 34.0 6 4.3 34.0 6 5.7 33.0 6 4.8 30.0 6 4.8 30.0 6 3.2
non-PD 37.0 6 7.3 33.0 6 6.1 32.0 6 6.5 30.0 6 7.4 26.0 6 10.3 30.0 6 9.6 37.0 31.0
Renal creatinine PD 0.29 6 0.1 0.39 6 0.2 0.41 6 0.2 0.33 6 0.1 0.24 6 0.1 0.20 6 0.1 0.29 6 0.1 0.25 6 0.1 0.24 6 0.1
clearance
ml/min





PD — 0.05 6 0.013 0.05 6 0.016 0.05 6 0.019 0.05 6 0.022 0.05 6 0.025 0.06 6 0.030 0.05 6 0.038 0.05 6 0.021
Drain volume
ml (3 hrs)
PD — 12.67 6 0.46 9.68 6 0.19 10.11 6 1.25 9.54 6 0.97 11.41 6 1.86 9.89 6 2.70 10.12 6 1.66 12.56 6 1.06
D/P creatinine
3 hrs




PD — — 92.7 6 1.35 92.4 6 0.43 93.4 6 0.46 88.7 6 1.73 92.3 6 1.53 92.8 6 1.24 92.0
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the relatively small contribution of the peritoneal clearance
to the overall clearance. Based on the creatinine clear-
ances, it can be calculated that the peritoneal clearance in
our experimental group contributes only 10% of the total
creatinine clearance. One of the reasons for this low
peritoneal clearance is the continuously negative peritoneal
ultrafiltration that was obtained with the daily use of one
dwell with 1.36% and one dwell with a 2.27% glucose
dialysate. The poor outflow was most certainly due to either
catheter malposition or ongoing peritonitis. In infection,
fluid drainage becomes difficult because the peritoneal
cavity becomes compartimentalized due to fibrin and ad-
hesions formation, resulting in the blocking of the perito-
neal catheter by the omentum. It should be stressed that no
omentectomy in these animals was performed. The second
reason for the low peritoneal clearances is the relatively
small dialysate volumes used in the two dwells (15 ml) and
the fact that peritoneal dialysis was only performed during
one quarter of the working day, with only one dwell of three
hours on Saturday and no exhange on Sunday. The perito-
neal clearance, however, remained constant. The perito-
neal membrane of these animals can be interpreted as
being hyperpermeable, as judged by both the high D/P
creatinine and high glucose absorption. This hyperperme-
ability can also be the consequence of the state of “chronic”
peritonitis that was present in all animals. A future treat-
ment schedule should consist of dialysate volumes of at
least 20 ml of glucose 3.86% and an additional long
overnight dwell preferably with a polyglucose solution.
After only two days of dialysis, the peritoneal leukocyte
count was elevated in the dialysate. Differential counts
revealed that most of these cells were macrophages and
monocytes. Granulocytosis of the effluent only appeared in
the presence of confirmed bacterial peritonitis. Further
refinements of our technique will hopefully solve some of
these problems, allowing the utilization of this model for
the study of “chronic peritoneal dialysis” in an uremic
animal.
CONCLUSIONS
The present article describes the experience of three
European research groups using different animal models of
peritoneal dialysis. The acute model developed in Stock-
holm is appropriate for the study of the normal physiology
of peritoneal transport and for a “first screening” of new
dialysis fluids. It has the advantage of being relatively
simple and cheap, but it does not allow conclusions on the
effects of long-term dialysis in uremia.
The Amsterdam model explores the mechanisms of
peritoneal defense against peritonitis and provides long-
term information on the cellular influx and the behavior of
the mesothelial cells during infection. The disadvantage is
that no dialysis is performed and that non-uremic animals
are studied.
The Gent model is by far the most complex, since it tries
to submit uremic animals to long-term peritoneal dialysis.
A number of difficulties are yet to be overcome before this
model will be working satisfactorily. Some of these models
will also have to be adapted to new findings.
It is hoped that in the future some of the European
laboratories will be able to combine their experience for
establishing a suitable animal model for long-term perito-
neal dialysis.
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